Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma

A select group of patients with hepatocellular carcinomas (HCC) benefit from surgical, radiologic, and systemic therapies that include a combination of anti-angiogenic and immune-checkpoint inhibitors. However, because HCC is generally asymptomatic in its early stages, this not only leads to late di...

Descripción completa

Detalles Bibliográficos
Autores principales: Mender, Ilgen, Siteni, Silvia, Barron, Summer, Flusche, Ann Marie, Kubota, Naoto, Yu, Chunhua, Cornelius, Crystal, Tedone, Enzo, Maziveyi, Mazvita, Grichuk, Anthony, Venkateswaran, Niranjan, Conacci-Sorrell, Maralice, Hoshida, Yujin, Kang, Rui, Tang, Daolin, Gryaznov, Sergei, Shay, Jerry W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233358/
https://www.ncbi.nlm.nih.gov/pubmed/37070671
http://dx.doi.org/10.1158/1535-7163.MCT-23-0039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233358/
https://www.ncbi.nlm.nih.gov/pubmed/37070671
http://dx.doi.org/10.1158/1535-7163.MCT-23-0039

Ejemplares similares